Global growth forecasts being downgraded due to factors like the Middle East conflict, which could reduce investor appetite for riskier growth stocks in the biotechnology sector.

Overall strength in the US economy and job market could provide a generally supportive backdrop for investment, though direct impact on biotechnology company funding might be less pronounced than for consumer-driven sectors.

General market uncertainty and volatility stemming from ongoing geopolitical events, such as the Middle East conflict, which can lead to cautious investor sentiment towards non-essential or high-growth sectors.